Comparative Pharmacology
Head-to-head clinical analysis: ANCEF versus CEFACLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCEF versus CEFACLOR.
ANCEF vs CEFACLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
250-500 mg orally every 8 hours
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."